this is notice post excerptRead More
Optipharm and Deargen, Introduced AI to find antigens (epitopes) that cause immune responses to liver cancer cells.Read More
DEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Especially for the case of COVID-19 treatment prediction using AI.Read More
Deep learning models predict old and new drugs that might successfully treat COVID-19.Read More
Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the deep-learning technology based AI model MT-DTI. The work is published on the BioRxiv.Read More
MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds
Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12.Read More
We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS.Read More
A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.
Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR).Read More
[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.
Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”.Read More
Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules.Read More